Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06717451 · ClinicalTrials.gov registry record

PS230005 Control-IQ 1.5 Post-Approval Study

A clinical trial of Type 1 Diabetes, sponsored by Tandem Diabetes Care.

Active
Registry status
144
Enrollment target
1
Study location

NCT06717451: Active study of Type 1 Diabetes, sponsored by Tandem Diabetes Care.

NCT06717451 is a study of Type 1 Diabetes that is active but no longer recruiting, run by Tandem Diabetes Care. The registered enrollment target is 144 participants, below the 766-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06717451, a study of Type 1 Diabetes, is active but no longer recruiting, sponsored by Tandem Diabetes Care.

ACTIVE NOT RECRUITING
Registry status
144 participants
Enrollment target
1
Study location

Study Summary

This 522 post-market surveillance study is a single-arm, decentralized prospective observational cohort study designed to collect safety data on Control-IQ technology v1.5 in children with type 1 diabetes ages 2 to \<6 years old. Participants will use Control-IQ technology v1.5 for 12 months in the real-world setting.

Primary Outcome

Overall incidence rate of SH events per 100 patient years during 12 months of Control-IQ use

Conditions Studied

Type 1 Diabetes

Interventions

  • DEVICE Control-IQ Technology v1.5

Study Locations (1)

California

  • Tandem Diabetes Care - San Diego

Trial Details

FieldValue
Enrollment Target 144 participants
Start Date 2025-01-30
Est. Completion 2026-08-11
Tandem Diabetes Care

13 total trials

What the registry record for NCT06717451 still lists

NCT06717451 is an observational study that tracks outcomes without assigning an intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, below the 766-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (81% lower).

The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Control-IQ Technology v1.5 is the first listed.

NCT06717451 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06717451 about?

NCT06717451 is a clinical study titled "PS230005 Control-IQ 1.5 Post-Approval Study". This 522 post-market surveillance study is a single-arm, decentralized prospective observational cohort study designed to collect safety data on Control-IQ technology v1.5 in children with type 1 diabetes ages 2 to \<6 years old. Participants will use Control-IQ technology v1.5 for 12 months in the ...

What is the current status of trial NCT06717451?

This trial is currently active not recruiting. The enrollment target is 144 participants. The study started on 2025-01-30. Estimated completion is 2026-08-11.

What conditions does trial NCT06717451 study?

This clinical trial studies the following conditions: Type 1 Diabetes.

What interventions are being tested in trial NCT06717451?

The interventions under investigation include: Control-IQ Technology v1.5 (DEVICE).

Who is sponsoring clinical trial NCT06717451?

This trial is sponsored by Tandem Diabetes Care, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06717451 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 1 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06717451's enrollment target sits among peer trials

144 40th of 198 higher than 158 of 198 other Type 1 Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01861106 · 144 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations

  • NCT03482245 · 144 participants · NA

    The Role of Circadian Clock Proteins in Innate and Adaptive Immunity

  • NCT03504683 · 144 participants · NA

    MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes

  • NCT03905603 · 144 participants · Early Phase 1

    Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06717451, the US trial registry maintained by the National Library of Medicine. NCT06717451 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.